Page 167 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 167
89Zr-immuno-PET in a phase I trial
Figure 2. Biodistribution of 89Zr-labeled-RG7356. (a) as function of time: maximum intensity projections at 1, 24 and 96 h p.i. for patient 12 (675mg dose cohort) (b) as function of total administered antibody dose: maximum intensity projections at 96 h p.i. for various dose cohorts (1, 100, 200, 450 and 675 mg).
Figure 3. Blood pool concentrations of 89Zr-RG7356 and RG7356. (a) Radioactivity concentrations of 89Zr- 8 RG7356 in blood pool as function of time. (b) Antibody concentrations of RG7356 in blood pool as function
of time. (c) AUC of the time antibody concentration curve of RG7356 in blood pool as function of antibody
dose.
Data is presented as mean, error bars represent SD.
165
